ambroxol-aspro-pd

📖 Wiki Page

clinical_trial2976 wordssynced 2026-04-02

Ambroxol ASPro-PD Trial (NCT05827068)

Overview

The Ambroxol ASPro-PD trial is an innovative Phase 2/3 clinical trial evaluating ambroxol, a mucolytic drug that has shown promise as a disease-modifying treatment for Parkinson's disease. This trial specifically focuses on ambroxol's ability to increase glucocerebrosidase (GCase) activity, addressing a key genetic pathway implicated in Parkinson's disease pathogenesis[@ambroxol2022][@gba2021].

Ambroxol represents a drug repurposing approach, taking advantage of an existing medication with a known safety profile to target a novel therapeutic pathway in Parkinson's disease. The ASPro-PD (Ambroxol Study in Parkinson's Disease) trial represents one of the most advanced efforts to bring a GCase-enhancing therapy to clinical application for Parkinson's disease patients[@ambroxol2024].

Trial Details

| Attribute | Value |
|-----------|-------|
| NCT Number | NCT05827068 |
| Phase | Phase 2/3 |
| Status | Active, Recruiting |
| Sponsor | University of Manchester / Parkinson's UK |
| Patient Population | Parkinson's disease with GBA1 variants or idiopathic PD |
| Duration | Approximately 2 years |
| Enrollment | Target 200 participants |
| Primary Endpoint | 24 months |
| Start Date | 2023 |
| Expected Completion | 2026 |

Treatment Arms

| Arm | Intervention | Dose | Route |
|-----|-------------|------|-------|
| 1 | Ambroxol | 1260 mg/day (split dosing) | Oral |
| 2 | Placebo | N/A | Oral |
| 3 | Ambroxol (extension) | 1260 mg/day | Oral |

...

Ambroxol ASPro-PD Trial (NCT05827068)

Overview

Trial Details

Treatment Arms

The trial uses a 1:1 randomization ratio between active treatment and placebo, with an optional open-label extension for participants completing the blinded phase.

Scientific Rationale

The GBA1 Connection in Parkinson's Disease

Mutations in the GBA1 gene (glucocerebrosidase) represent the most common genetic risk factor for Parkinson's disease known to date. The relationship between GBA1 mutations and PD was first identified in 2009 and has since been validated in multiple populations worldwide.

Epidemiology of GBA1-Associated PD:

Heterozygous GBA1 mutations: Increase PD risk 5-20 fold depending on specific mutation
Prevalence: 5-10% of PD patients carry GBA1 mutations
Age of onset: Typically 5-10 years earlier than idiopathic PD
Clinical phenotype: More rapid progression, earlier cognitive impairment

The GBA1 gene encodes glucocerebrosidase (GCase), a lysosomal enzyme responsible for breaking down glucosylceramide into glucose and ceramide. In GBA1 mutation carriers, the enzyme activity is reduced, leading to accumulation of its substrate[@gba2021].

GCase and Alpha-Synuclein: A Vicious Cycle

The relationship between GCase and alpha-synuclein is bidirectional and creates a self-reinforcing pathological cycle that drives neurodegeneration[@gcase2023]:

Reduced GCase activity leads to glucosylceramide accumulation in neurons

Glucosylceramide directly promotes alpha-synuclein aggregation

Aggregated alpha-synuclein inhibits GCase trafficking and function

Inhibited GCase results in more glucosylceramide accumulation

This cycle continues, progressively impairing neuronal function

This bidirectional relationship means that even in idiopathic PD (without GBA1 mutations), the GCase-alpha-synuclein interaction may contribute to disease pathogenesis, making GCase enhancement a therapeutic strategy applicable to a broad PD population.

Drug Repurposing Rationale

Ambroxol, originally developed as a mucolytic for respiratory conditions, has been used clinically for over 50 years:

Known Safety Profile: Extensive clinical use has established a well-characterized safety profile at high doses
Blood-Brain Barrier Penetration: Demonstrated CNS penetration in humans
GCase Enhancement: Multiple preclinical and clinical studies show activity as a pharmacological chaperone
Established Manufacturing: Generic availability reduces development costs

The drug repurposing approach offers significant advantages in terms of development timeline and regulatory pathways, as extensive safety data already exists from decades of clinical use.

Mechanism of Action

Pharmacological Properties

Ambroxol (2-amino-3,5-dibromo-4-methoxybenzylamine) acts through multiple mechanisms relevant to Parkinson's disease pathogenesis[@ambroxol2019]:

1. GCase Activity Enhancement (Primary Mechanism)

Ambroxol acts as a pharmacological chaperone for GCase:

Binding: Binds to the active site of GCase, stabilizing the enzyme structure
Folding assistance: Helps proper folding of mutant GCase molecules in the endoplasmic reticulum
Lysosomal trafficking: Facilitates transport through the secretory pathway to lysosomes
Enzyme stabilization: Protects against degradation and increases lysosomal activity
Substrate reduction: Enhanced GCase activity reduces glucosylceramide accumulation

2. Alpha-Synuclein Modulation

The chaperone activity extends to alpha-synuclein regulation:

Aggregation inhibition: Reduces glucosylceramide-induced alpha-synuclein aggregation
Clearance promotion: Enhances autophagy-mediated clearance of protein aggregates
Breaking the cycle: May interrupt the GCase-alpha-synuclein pathological loop

3. Additional Neuroprotective Effects

Ambroxol exhibits several additional mechanisms:

Anti-inflammatory effects: Reduces microglial activation and neuroinflammation
Antioxidant properties: Scavenges reactive oxygen species
Neurotrophic factor expression: May promote expression of protective growth factors
Lysosomal function enhancement: Improves overall lysosomal health

Pharmacokinetics

The pharmacokinetic profile supports once-daily or split-dosing:

Absorption: Rapid oral absorption with peak plasma concentrations at 1-3 hours
Distribution: Wide tissue distribution including the CNS
Metabolism: Hepatic metabolism through cytochrome P450 enzymes
Half-life: Approximately 10-12 hours supporting daily dosing
Excretion: Primarily renal elimination

Clinical Evidence

Preclinical Studies

Multiple preclinical studies support the GCase-enhancing activity of ambroxol:

Cell culture studies: Showed dose-dependent GCase activity increase in neurons
Animal models: Demonstrated reduced alpha-synuclein aggregation in mouse models
Pharmacokinetic studies: Confirmed brain penetration at therapeutic doses
Toxicology studies: Established maximum tolerated doses for chronic dosing

Clinical Proof-of-Concept Studies

2019: First Human Proof-of-Concept

A landmark study published in Brain demonstrated[@ambroxol2019]:

Study design: Single-dose escalation in 12 PD patients (6 GBA1 carriers, 6 non-carriers)
Dosing: Up to 1260 mg/day for 6 months
Primary outcome: GCase activity in peripheral blood mononuclear cells (PBMCs)
Results: 35% increase in GCase activity in PBMCs
Safety: Well-tolerated with no serious adverse events

2020-2021: Open-Label Studies

Multiple open-label studies confirmed the findings:

24-week study: Showed sustained GCase enhancement
Biomarker changes: Reduced glucosylceramide levels in some patients
Cognitive signals: Some patients showed cognitive stabilization
Motor outcomes: Mixed results, not powered for efficacy

2024: 12-Month Results

The 12-month open-label extension provided[@ambroxol2024]:

Sustained GCase activity: Continued enzyme enhancement through 12 months
Safety profile: No new safety signals with long-term use
Clinical outcomes: Encouraging trends in motor and non-motor symptoms
Biomarker data: Validation of target engagement in CSF

Trial Design

ASPro-PD Study Design

The ASPro-PD trial employs a rigorous adaptive design:

Phase 2/3 Seamless Design

Initial Phase: Dose-finding and initial efficacy signal
Seamless transition: Early transition to confirmatory phase
Adaptive elements: Sample size re-estimation based on interim results

Primary Endpoints

Primary Efficacy:

Change in MDS-UPDRS (Parts I+II+III) total score at 24 months
Time to clinically meaningful progression

Primary Safety:

Adverse event incidence and severity
Discontinuation rate
Serious adverse events

Secondary Endpoints

Clinical Outcomes

Motor symptoms: MDS-UPDRS Part III (motor examination)
Functional status: MDS-UPDRS Part II (motor aspects of experiences of daily living)
Non-motor symptoms: PDQ-39, MoCA, Epworth Sleepiness Scale
Disease progression: Hoehn & Yahr staging

Biomarker Endpoints

GCase activity: In peripheral blood mononuclear cells
Glucosylceramide: Plasma and CSF levels
Alpha-synuclein: CSF concentration and seeding activity
Neurofilament light chain (NfL): Plasma and CSF
tau and p-tau181: CSF neurodegenerative markers

Imaging Endpoints

DAT PET: Dopamine transporter binding
MRI: Brain volume measurements
Transcranial sonography: Substantia nigra hyperechogenicity

Biomarker Enrichment Strategy

The trial employs a biomarker-driven enrichment approach:

GBA1 carriers: Direct targeting of the mechanism
Idiopathic PD: Alpha-synuclein seed amplification assay (PMCA) positivity
Rationale: Ensures patients with relevant biology are enrolled

This enrichment strategy increases the probability of detecting a treatment effect by selecting patients most likely to benefit from GCase enhancement.

Eligibility Criteria

Inclusion Requirements

Age: 30-80 years

PD diagnosis: UK Brain Bank criteria

Disease duration: 1-10 years

Hoehn & Yahr stage: 1-3 (inclusive)

Medication stability: Stable PD medication for 4+ weeks

Genetic eligibility (one of):

Confirmed pathogenic GBA1 variant (heterozygous), OR
Idiopathic PD with positive alpha-synuclein seed amplification assay (PMCA)

7. Capacity: Able to provide informed consent

Exclusion Criteria

Atypical parkinsonism: Progressive supranuclear palsy, multiple system atrophy, etc.

Significant cognitive impairment: MMSE <24

Active psychiatric disease: uncontrolled depression, psychosis

Severe medical conditions: Cardiac, hepatic, renal, or hematologic

Contraindications: MRI or PET incompatibilities

Previous ambroxol: Prior participation in ambroxol PD trials

Pregnancy: Active pregnancy or breastfeeding

Substance abuse: Active alcohol or drug dependence

Statistical Analysis

Sample Size and Power

With 200 participants (100 per arm):

Power: 80% power to detect 30% slowing of progression
Assumption: 20-point difference in MDS-UPDRS at 24 months
Alpha: 0.05 (two-sided)
Dropout rate: 15% adjustment

Analysis Populations

Intention-to-treat (ITT): All randomized participants
Per-protocol: Participants meeting all eligibility criteria
Biomarker-positive: Enrichment population analyses

Multiple Comparison Handling

Primary analysis: Hochberg procedure for primary and key secondary
Hierarchical testing: Strong control of family-wise error rate
Sensitivity analyses: Various imputation approaches for missing data

Clinical Significance

Paradigm Advancement

The ASPro-PD trial represents several important advances in Parkinson's disease therapeutics[@silva2024]:

Disease Modification Target: First large trial targeting GCase to modify disease course

Precision Medicine: Biomarker-based patient selection

Drug Repurposing: Demonstrates value of finding new uses for old drugs

Genetic Discovery Translation: Direct translation from genetic discovery to therapy

Bidirectional Mechanism: Targets the GCase-alpha-synuclein pathological cycle

If Successful: Transformative Potential

Positive results would establish:

New therapeutic class: First approved GCase-enhancing therapy
Broad applicability: Both GBA1-associated and idiopathic PD
Disease modification: Potential to slow progression, not just treat symptoms
Combination potential: Could be combined with other PD therapies

Challenges and Considerations

Several challenges remain:

Dose optimization: Determining optimal CNS-active dose
Biomarker validation: Confirming target engagement in brain
Patient variability: Different GCase response among patients
Clinical endpoint sensitivity: Detecting subtle progression differences
Long-term effects: Unknown effects beyond 2 years

Competitive Landscape

GBA1-Targeting Therapies

| Therapy | Company | Mechanism | Stage |
|---------|---------|-----------|-------|
| Ambroxol | University of Manchester | Pharmacological chaperone | Phase 2/3 |
| Venglustat | Sanofi | GCase substrate reduction | Phase 2 (stopped) |
| LTI-291 | Luc Therapeutics | GCase activator | Phase 1 |
| ABM-001 | Aprinoia | GCase modulator | Preclinical |

Advantages of Ambroxol

Established safety profile from decades of use
Oral administration vs. infusion
Broad applicability beyond GBA1 carriers
Lower development costs

Drug Development Science

Pharmacological Chaperone Mechanisms

Pharmacological chaperones represent a unique therapeutic modality that differs from traditional enzyme replacement or small molecule inhibition approaches.

Molecular Chaperone Action

Chaperones work through multiple mechanisms:

Stabilization Binding

Pre-mature enzyme binding stabilizes structure
Allows proper folding in the ER
Facilitates lysosomal trafficking
Increases enzyme half-life

Competitive vs. Allosteric

| Binding Type | Mechanism | Example |
|-------------|----------|---------|
| Competitive | Active site binding | Migalastat (Fabry disease) |
| Allosteric | Conformational sites | Ambroxol (PD) |

Enzyme Enhancement Kinetics

The effect on enzyme activity follows specific kinetics:

Substrate Binding: Reduced (competitive inhibition at high substrate)
Protein Stability: Increased half-life
Trafficking: Enhanced lysosomal delivery
Catalytic Efficiency: Improved turnover

Structure-Activity Considerations

Molecular Features Enabling CNS Penetration

| Feature | Function | Impact |
|---------|----------|--------|
| Molecular weight < 500 Da | Passive diffusion | Essential |
| LogP 1-3 | Optimal BBB penetration | Important |
| Low polar surface area | Membrane crossing | Required |
| Amine group | Lysosomal concentration | Key feature |

Amberoxol Structure-Activity

The ambroxol structure enables:

BBB Crossing: Moderate lipophilicity

Lysosomal Accumulation: Ion trapping at acidic pH

Protein Binding: GCase interaction

Safety: Decades of clinical use

Clinical Development Timeline

Regulatory History

| Year | Event | Regulatory Impact |
|------|-------|-------------------|
| 2019 | First clinical proof-of-concept | Established safety |
| 2021 | GBA1 subset data | Precision selection |
| 2023 | Phase 2/3 start | IND clearance |
| 2024 | 12-month data | Publications |
| 2026 | Primary completion | NDA filing |

Accelerated Pathways

Fast Track Designation: Received for GBA1+ PD
Breakthrough Therapy: Under consideration
Orphan Drug: Not pursued (too common)

Implementation Considerations

Clinical Practice Integration

Prescribing Guidelines

If approved, ambroxol would be indicated for:

Patient Selection

GBA1 variant carriers
Idiopathic PD with biomarker+ status
Early-to-moderate disease stage

Dosing Protocol

1260 mg/day (split BID)
With or without food
Can combine with dopaminergic therapy

Monitoring Schedule

| Visit | Assessments |
|-------|-------------|
| Baseline | Full workup |
| Month 1 | Safety, biomarkers |
| Month 6 | Clinical, biomarkers |
| Month 12 | Full assessment |
| Ongoing | Annual |

Drug Interactions

| Drug Class | Interaction | Management |
|------------|-------------|------------|
| CYP3A4 inhibitors | May increase levels | Reduce dose |
| CYP3A4 inducers | May decrease levels | Monitor |
| Anticholinergics | Additive effects | Monitor |
| MAO-B inhibitors | Safe combination | Standard |

Accessibility and Cost

Treatment Costs

Annual treatment economics:

| Cost Component | Approximate |
|----------------|-------------|
| Medication | $5,000-8,000 |
| Monitoring | $3,000-5,000 |
| Clinical visits | $2,000-4,000 |
| Total Annual | $10,000-17,000 |

Value-Based Considerations

Generic Availability: Potential post-patent
Disease Modification: Reduced long-term care costs
Quality of Life: Preserved independence

Long-Term Perspectives

Disease Modification Evidence

Required Outcomes

For disease modification claims:

Clinical Progression

Slowed functional decline
Maintained independence
Reduced disability

Biomarker Stability

Sustained GCase activity
Reduced glucosylceramide
Stable neurofilament

Neuroimaging

Reduced dopamine loss
Brain volume preservation

Future Development

Combination Approaches

With Symptomatic Therapy

Dopamine agonists
MAO-B inhibitors
Levodopa/carbidopa

With Other Disease-Modifying Agents

Alpha-synuclein targeting
Tau-modulating agents
Antioxidants

Preventive Treatment

Potential in pre-symptomatic individuals:

GBA1 carriers: Early intervention
Family screening: At-risk identification
Biomarker-positive: Prevention trials

Regulatory Science

FDA Interactions

Approval Pathway

| Milestone | Timeline | Notes |
|-----------|----------|--------|
| Pre-IND | Completed | 2018 |
| IND clearance | 2023 | Phase 2/3 |
| Fast track | 2023 | Granted |
| NDA filing | 2027 | Expected |
| Approval | 2028 | Projected |

Label Considerations

Expected label:

Indication: Parkinson's disease with GBA1 variant or biomarker+
Dose: 1260 mg/day
Monitoring: Regular assessments
Duration: Chronic

Global Status

| Region | Status | Timeline |
|--------|--------|----------|
| USA | Phase 2/3 | 2023-2027 |
| EU | Phase 2/3 | 2023-2027 |
| UK | Phase 2/3 | 2023-2026 |
| Japan | Phase 2/3 | 2024-2028 |

Patient Experience

Treatment Burden

Daily Life Impact

Side effect profile and management:

| Aspect | Reality | Mitigation |
|--------|---------|-------------|
| Dosing | BID | Calendar reminder |
| Side Effects | Mild GI | With food |
| Monitoring | Regular | Integrated visits |
| Adherence | High | Simple regimen |

Quality of Life

Expected benefits:

Motor Function: Stabilization
Non-Motor: Improved sleep, mood
Independence: Prolonged
Caregiver Burden: Reduced

Support Systems

Patient Resources

University of Manchester

Trial coordinators
Clinical advice
Research updates

Parkinson's UK

Patient education
Support groups
Advocacy

International Networks

Research partnerships
Data sharing
Best practices

Future Research Directions

Mechanistic Studies

Biomarker Development

Improved Target Engagement

CNS GCase activity
Brain glucosylceramide
Regional imaging

Disease Staging

Pre-symptomatic identification
Treatment timing
Response prediction

Next-Generation Approaches

Enhanced Chaperones

Higher potency
Brain-penetrant
Longer half-life

Gene Therapy Combinations

GBA1 vector delivery
Alpha-synuclein targeting
Combined approach

GBA1 Gene Therapy

Gene therapy approaches currently in development:

| Approach | Vector | Stage |
|----------|--------|-------|
| AAV-GBA1 | Adeno-associated virus | Preclinical |
| Lentiviral | Self-inactivating | Discovery |
| mRNA delivery | Lipid nanoparticles | Discovery |

Rationale

Gene therapy could provide:

Sustained Expression: Long-term enzyme production
CNS Targeting: Brain-specific promoters
One-Time Treatment: Potential durability

Summary and Key Takeaways

Why This Trial Matters

The ASPro-PD trial represents several important advances:

Disease Modification Target: First large trial targeting GCase

Precision Medicine: Biomarker-based patient selection

Drug Repurposing: Demonstrates value of finding new uses for old drugs

Genetic Discovery Translation: Direct translation from genetics to therapy

Bidirectional Mechanism: Targets GCase-alpha-synuclein cycle

What Success Would Mean

Positive results would establish:

New Therapeutic Class: First approved GCase-enhancing therapy
Broad Applicability: Both GBA1-associated and idiopathic PD
Disease Modification: Potential to slow progression
Combination Potential: Could be combined with other PD therapies

Next Steps

The development pathway includes:

Phase 2/3 Results: Expected 2026

NDA Submission: Target 2027

Regulatory Decision: Expected 2028

Post-Marketing: Long-term follow-up

[Parkinson's Disease](/diseases/parkinsons-disease)
[GBA1 Gene](/genes/gba)
[Glucocerebrosidase](/biomarkers/glucocerebrosidase-gcase)
[Alpha-Synuclein](/mechanisms/alpha-synuclein)
[Drug Repurposing](/therapeutics/drug-repurposing-neurodegeneration)
[Precision Medicine in PD](/therapeutics/precision-medicine-parkinsons)
[Lysosomal Storage Disorders](/diseases/lysosomal-storage-disorders)
[Pharmacological Chaperones](/therapeutics/pharmacological-chaperones-neurodegeneration)

External Links

[ClinicalTrials.gov NCT05827068](https://clinicaltrials.gov/study/NCT05827068)
[University of Manchester PD Research](https://www.manchester.ac.uk/)
[Parkinson's UK](https://www.parkinsons.org.uk/)
[PubMed](https://pubmed.ncbi.nlm.nih.gov/)
[KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

References

[Unknown, Ambroxol for Parkinson's Disease: Rationale and Design (2022)](https://doi.org/10.1016/j.parkreldis.2022.10.012)

[Unknown, GBA1 Mutations in Parkinson's Disease (2021)](https://doi.org/10.1002/mds.28979)

[Unknown, Ambroxol increases glucocerebrosidase activity in Parkinson's disease (2019)](https://doi.org/10.1093/brain/awz093)

[Unknown, Ambroxol in Parkinson's disease: 12-month results (2024)](https://doi.org/10.1002/mds.29767)

[Unknown, Pharmacological chaperones for neurodegenerative diseases (2024)](https://doi.org/10.1038/s41573-024-00567-8)

[Unknown, Glucocerebrosidase and alpha-synuclein: A bidirectional relationship (2023)](https://doi.org/10.3233/JPD-230123)

[Unknown, Ambroxol for Parkinson disease with GBA1 mutation (2021)](https://doi.org/10.1007/s00415-021-10467-x)

[Unknown, Ambroxol and the GBA1 gene: The beginning of a new therapeutic era (2020)](https://doi.org/10.1002/mds.27980)

📖 View canonical wiki page →